Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial
Jn. King et al., Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial, APPL ANIM B, 67(4), 2000, pp. 255-275
The efficacy and tolerability of clomipramine in the treatment of separatio
n anxiety in dogs was tested in a prospective, randomized, double-blind, pl
acebo-controlled, parallel-group, international multicenter clinical trial.
For a diagnosis of separation anxiety, dogs had to exhibit at least one of
the following signs in the absence of their owner: destruction, defecation
, urination and/or vocalization, as well as the behaviour suggestive of "hy
per-attachment" to their owner. A total of 95 dogs were randomized to recei
ve one of the three treatments for 2-3 months: "standard-dose'' clomipramin
e (1 to <2 mg/kg, PO, q. 12 h); "low-dose" clomipramine (0.5 to <1 mg/kg, P
O, q. 12 h); and placebo (PO, q. 12 h). All dogs received behavioural thera
py. Dogs were examined at four time points (days 0, 28, 56 and 84) after th
e initiation of therapy. Improvement in each dog's behaviour at days 28, 56
and 84 was evaluated in comparison to its behaviour at day 0.
The results showed that, compared to placebo, dogs receiving standard-dose
clomipramine were rated improved at least three times faster for the signs
destruction, defecation and urination. At most time points, more dogs in th
e standard-dose clomipramine group were rated improved for the signs destru
ction, defecation and urination, and in an owner's global assessment of the
dog's overall behaviour (p < 0.05 at certain time points). However, there
were no statistically significant differences at any time point between the
standard dose and the placebo groups in the sign vocalization. The low-dos
e clomipramine group produced no statistically significant effect when comp
ared with placebo. Mild and transient vomiting was noted as a side effect o
f clomipramine in a small number of dogs.
It is concluded that addition of standard-dose (1 to <2 mg/kg, PO, q. 12 h)
clomipramine to conventional behavioural therapy for 2-3 months ameliorate
d the signs of separation anxiety in dogs. (C) 2000 Published by Elsevier S
cience B.V. All rights reserved.